- Home
- NXTT vs NXTC Comparison
NXTT vs NXTC Comparison
Compare NXTT & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTT
- NXTC
- Stock Information
- Founded
- NXTT 2019
- NXTC 2015
- Country
- NXTT China
- NXTC United States
- Employees
- NXTT N/A
- NXTC N/A
- Industry
- NXTT
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- NXTT
- NXTC Health Care
- Exchange
- NXTT NYSE
- NXTC Nasdaq
- Market Cap
- NXTT 19.5M
- NXTC 21.6M
- IPO Year
- NXTT N/A
- NXTC 2019
- Fundamental
- Price
- NXTT $1.31
- NXTC $0.72
- Analyst Decision
- NXTT
- NXTC Strong Buy
- Analyst Count
- NXTT 0
- NXTC 2
- Target Price
- NXTT N/A
- NXTC $4.00
- AVG Volume (30 Days)
- NXTT 334.1K
- NXTC 62.2K
- Earning Date
- NXTT 04-15-2025
- NXTC 03-20-2025
- Dividend Yield
- NXTT N/A
- NXTC N/A
- EPS Growth
- NXTT N/A
- NXTC N/A
- EPS
- NXTT 3.59
- NXTC N/A
- Revenue
- NXTT $1,133,308.00
- NXTC N/A
- Revenue This Year
- NXTT N/A
- NXTC N/A
- Revenue Next Year
- NXTT N/A
- NXTC N/A
- P/E Ratio
- NXTT $0.37
- NXTC N/A
- Revenue Growth
- NXTT N/A
- NXTC N/A
- 52 Week Low
- NXTT $0.94
- NXTC $0.66
- 52 Week High
- NXTT $6.66
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- NXTT 41.83
- NXTC 40.34
- Support Level
- NXTT $1.03
- NXTC $0.66
- Resistance Level
- NXTT $1.23
- NXTC $0.79
- Average True Range (ATR)
- NXTT 0.15
- NXTC 0.06
- MACD
- NXTT 0.03
- NXTC 0.00
- Stochastic Oscillator
- NXTT 66.67
- NXTC 42.21
About NXTT NEXT TECHNOLOGY HOLDING INC
Next Technology Holding Inc pursues two corporate strategies. One business strategy is to continue providing software development services, and the other strategy is to acquire and hold Bitcoin. It provides AI-enabled software development services to its customers, which include developing, designing, and implementing various SAAS software solutions for businesses of all types, including industrial and other businesses. Its bitcoin acquisition strategy generally involves acquiring bitcoin with its liquid assets that exceed working capital requirements, and from time to time, subject to market conditions, issuing debt or equity securities or engaging in other capital raising transactions to use the proceeds to purchase bitcoin.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.